Webinar Date/Time: Thu, Apr 27, 2023 10:00 AM EDT
Calling all screening scientists! How will you fill the discovery funnel with high-quality hits? Scaling-up and accelerating mass spectrometry data analysis is a surefire way.
Register Free: https://www.biopharminternational.com/bp_w/screening-labs
Event Overview:
While mass spectrometry (MS) delivers better screening results in less time, the resulting tsunami of complex assays creates a data analysis bottleneck, which can take days up to weeks to overcome. These challenges are a thing of the past with Genedata Screener® for MS. Integrated with a wide range of MS instrumentation, Genedata Screener now includes ready-to-go analysis workflows for typical assay formats.
This webinar will demonstrate how the new MS application analyzes and reports on assay formats, such as multiplexed affinity selection MS (ASMS), multiple reaction monitoring (MRM), and various covalent binding assays. Scientists using MS as a technology to scale up and accelerate identification and validation now have an automated data analysis solution that matches MS throughput, which:
Key Learning Objectives:
Featured Speaker:
Matthew Green, PhD
Mass Spectrometry Screening Lead
Genedata
At Genedata, Matthew Green PhD leads a diverse range of projects with many of the best pharmaceutical and biotechnology companies. With a background in biophysics and software development, he is an expert in automating analysis to increase insight and throughput to deliver digitization at an organizational level.
Matthew’s scientific and professional career has had an exciting trajectory through various complimentary cutting-edge fields, providing him uniquely well rounded insight into international biological research and the modern skills required to undertake it.
After a 'wet' PhD and Post-Docs in Molecular Biology, Matthew moved into biophysics, working at several of Europe's synchrotrons, and contributed to a successful spin-out venture now known as Akeso Biomedical. He later transitioned into bioinformatics and software development at the European Bioinformatics Institute, where he held several positions on international projects—most notably, construction of the Human Cell Atlas Data Coordination Platform in collaboration with developers at CZI and the Broad Institute.
Register Free: https://www.biopharminternational.com/bp_w/screening-labs
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.